Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- New lipid-based pathway discovered as key to memory formation - 25th June 2025
- Crucial link could explain how Alzheimer’s takes hold - 25th June 2025
- Understanding Your Mind Can Improve Daily Life - 25th June 2025